At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Pegloticasebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients With Uncontrolled Gout Who Have Undergone Kidney Transplantation
In Brief
A Phase 4 clinical trial evaluating Pegloticase for Uncontrolled Gout and Kidney Transplant. Completed, enrolled 20 participants across 8 sites.
Detailed Summary
The primary objective of this study is to evaluate the effect of pegloticase on the response rate of sustained serum uric acid (sUA) reduction to sUA \< 6 mg/dL during Month 6 of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUncontrolled Gout, Kidney Transplant
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
First PostedSep 2019
Primary CompletionJul 2021
Study CompletionSep 2021
TodayJul 2026
First PostedSep 12, 2019
Enrollment StartSep 9, 2019
Primary CompletionJul 6, 2021
Study CompletionSep 7, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.8 years ago
Interventions
Pegloticasebiological
intravenous (IV) infusion